2016
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters 2016, 649: 147-155. PMID: 27916636, PMCID: PMC5482215, DOI: 10.1016/j.neulet.2016.11.064.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychiatric disordersStress-related psychiatric disordersAlternative pharmacologic treatmentsPutative neurobiological underpinningsGlutamate-modulating agentsTrauma-related disordersGlutamatergic abnormalitiesGlutamate dysregulationPharmacologic treatmentPharmacologic interventionsGlutamatergic functionGlutamate neurotransmissionMillions of individualsHuman studiesCardinal featuresStress disorderDisordersNeurobiological underpinningsRelated future directionsEvidenceChronicDysfunctionNeurotransmissionSubject data
2013
Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia
Anticevic A, Cole MW, Repovs G, Savic A, Driesen NR, Yang G, Cho YT, Murray JD, Glahn DC, Wang XJ, Krystal JH. Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia. Frontiers In Psychiatry 2013, 4: 169. PMID: 24399974, PMCID: PMC3871997, DOI: 10.3389/fpsyt.2013.00169.Peer-Reviewed Original ResearchNMDA receptor antagonistFunctional neuroimaging toolsFunctional imaging studiesNeural system dysfunctionsRecent neuroimaging studiesKetamine administrationRecent findingsPharmacological treatmentSynaptic dysfunctionReceptor antagonistSystem dysfunctionPathophysiologic hypothesesBipolar illnessHealthy subjectsResting-state neuroimagingHealthy volunteersClinical investigationHealthy humansPsychiatric disordersCardinal featuresPharmacological manipulationPsychiatric conditionsLocal circuitsImaging studiesNeuropsychiatric diseases